← 返回

头颈部肿瘤患者血液学参数与 PET/CT 代谢参数的相关性

英文原题:Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer.

查看英文原题

Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer.

PubMed 2022/08/13(内容时间) Radiat Oncol Q1 · IF 3.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

在未接受任何治疗(如根治性放(化)疗或肿瘤手术后继以辅助 RT)的 HNSCC 患者中,基线 PLR 与 MTV 和 TLG 相关,但与 SUV 无关。NLR 与我们研究中分析的任何 PET/CT-MPs 均不相关。需要验证性研究,肿瘤微环境、宿主炎症与 FDG-PET/CT 指标之间潜在的相互作用值得进一步研究。

研究思路结论见上方概要

全身炎症可预测癌症患者的总生存期,并与癌症肿瘤微环境中免疫细胞的密度相关,而后者又与18F-氟脱氧葡萄糖(FDG)-正电子发射断层扫描/计算机断层扫描(PET/CT)代谢参数(MPs)相关。微环境中TIL(肿瘤浸润淋巴细胞)(TILs)的密度有潜力成为一种生物标志物,可在临床上用于优化口咽部头颈部鳞状细胞癌(HNSCC)患者的筛选。关于全身炎症与PET/CT-MPs之间关联的数据很少甚至没有,尤其是在HNSCC中。本研究旨在评估宿主炎症标志物,即血液中性粒细胞与淋巴细胞比值(NLR)和血小板与淋巴细胞比值(PLR),与未经治疗的非转移性(cM0)HNSCC患者FDG-PET/CT衍生的原发肿瘤PET/CT-MPs标准化摄取值(SUV)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)之间的相关性。我们假设基线时的NLR和PLR与PET/CT-MPs呈正相关。

对连续接受过治疗前 PET/CT 检查的 HNSCC 患者进行了回顾性分析。NLR 和 PLR 使用任何治疗开始前 10 天内测量的全血细胞计数计算。NLR 和 PLR 与 PET/CT-MPs 之间的相关性采用 Spearman's rho 检验进行评估。

共分析71例患者。1年、2年和3年总生存期(OS)率分别为86%、76%和68%。发现PLR与MTV(rho = 0.26,P = .03)和TLG(rho = 0.28,P = .02)相关,但与最大SUV或平均SUV无关。NLR与所分析的PET/CT-MPs之间无相关性。在单变量和多变量分析中,TLG与更差的生存相关,但其他PET/CT-MPs均与OS或疾病特异性生存(DSS)无关。在单变量和多变量分析中,NLR和PLR与OS和DSS相关。

展开英文摘要原文

Systemic inflammation is predictive of the overall survival in cancer patients and is related to the density of immune cells in the tumor microenvironment of cancer, which in turn correlates with 18 F -fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) metabolic parameters (MPs). The density of tumor-infiltrating lymphocytes (TILs) in the microenvironment has the potential to be a biomarker that can be used clinically to optimize patient selection in oropharyngeal head and neck squamous cell carcinoma (HNSCC). There is little to no data regarding the association of systemic inflammation with PET/CT-MPs, especially in HNSCC. This study aimed to evaluate the correlation between markers of host inflammation, namely blood neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), with the PET/CT-MPs standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) of the primary tumor, derived from FDG-PET/CT in patients with nonmetastatic (cM0) HNSCC before treatment. We hypothesized that NLR and PLR at baseline are positively correlated with PET/CT-MPs.

A retrospective review of consecutive patients with HNSCC with a pretreatment PET/CT was performed. NLR and PLR were computed using complete blood counts measured within 10 days before the start of any treatment. The correlation between NLR and PLR with PET/CT-MPs was evaluated with Spearman's rho test.

Seventy-one patients were analyzed. Overall survival (OS) at 1, 2, and 3 years was 86%, 76%, and 68%. PLR was found to be correlated with MTV (rho = 0.26, P = .03) and TLG (rho = 0.28, P = .02) but not with maximum SUV or mean SUV. There was no correlation between NLR and the analyzed PET/CT-MPs. TLG was associated with worse survival in uni- and multivariable analysis, but no other PET/CT-MPs were associated with either OS or disease-specific survival (DSS). NLR and PLR were associated with OS and DSS on uni- and multivariable analysis.

In patients with HNSCC before any treatment such as definitive radio (chemo)therapy or oncologic surgery followed by adjuvant RT, baseline PLR correlated with MTV and TLG but not with SUV. NLR was not correlated with any PET/CT-MPs analyzed in our study. Confirmatory studies are needed, and a potential interaction between tumor microenvironment, host inflammation, and FDG-PET/CT measures warrants further investigation.

论文信息

作者
Bojaxhiu B、Sinovcic D、Elicin O、Templeton AJ、Shelan M、Wartenberg J、Alberts I、Rominger A
单位
Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Freiburgstrasse, 3010, Bern, Switzerland. beat.bojaxhiu@insel.ch.Switzerland
期刊
Radiation oncology (London, England)2022 Aug 13
原文标识
PubMed 35964056 · DOI 10.1186/s13014-022-02112-4